Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolterodine ER with Behavioral Intervention in OAB
NCT00230789Phase 4Completed
- Sponsor
- Viatris
- Start
- Oct 2005
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tolterodine in overactive bladder (OAB), sponsored by Viatris. Primary endpoint: Subject satisfaction with treatment at 16 weeks. Started Oct 2005; status: completed.
02
Drugs
tolterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00230789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00230789.